Monopar Therapeutics Inc (MNPR) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access MNPR Annual Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Monopar Therapeutics Inc.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent52.76
Cash & Short-term Investments52.00
Other Current Assets0.00
Total Current Assets134.76
Other Assets, Noncurrent82.22
Total Assets134.98
Liabilities
Accounts Payable and Accrued Liabilities, Current LI4.02
Total Current Liabilities4.02
Total Long-term Debt0.00
Other liabilities, Noncurrent0.11
Total Liabilities4.12
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock229.47
Retained Earnings / Accumulated Deficit-98.72
Accumulated Other Comprehensive Income0.09
Other Equity0.09
Common Stockholder's Equity130.85
Total Stockholder's Equity130.85
Liabilities & Stockholder's Equity134.98
4 historic quarters locked

Sign in to unlock the full Monopar Therapeutics Inc balance sheet history.

About Monopar Therapeutics Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001437749-26-027164

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.